DNAJC27-AS1: A Potential Drug Target and Biomarker (G729723)

Target Name: DNAJC27-AS1

NCBI ID: G729723

DNAJC27-AS1

Other Name(s): DNAJC27 antisense RNA 1 (non-protein coding) | DNAJC27 antisense RNA 1

DNAJC27-AS1: A Potential Drug Target and Biomarker

Introduction

DNAJC27-AS1, a non-protein coding RNA (ncRNA), has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure, location, and expression patterns make it an attractive target for the development of new therapeutic approaches. In this article, we will explore the biology of DNAJC27-AS1, its potential as a drug target, and its potential as a biomarker for various diseases.

Structure and Expression

DNAJC27-AS1 is a 24.1 kilobase (kb) RNA molecule with 19 exons. It is located on the X chromosome and has a unique structure, with a 5' end that is rich in conserved sequence, 3' end that has a single AUG open at its start, and a middle regions that are relatively stable. The RNA has a calculated molecular weight of 19.8 kDa and a base pairing pattern of GAGC/AUG.

DNAJC27-AS1 is expressed in various tissues and cells, including human placenta, brain, and cancer cells. Its expression level varies depending on the tissue and developmental stage, but it is generally low in normal tissues. In cancer cells, DNAJC27 -AS1 is highly expressed and can be used as a biomarker for the diagnosis and prognosis of various cancers.

Potential Drug Target

DNAJC27-AS1 has been identified as a potential drug target due to its unique structure and expression patterns. Its 5' end is rich in conserved sequences, 3' end has a single AUG open at its start, and middle regions are relatively stable, making it a potential protein-coding RNA (pcRNA) target. Several studies have shown that inhibiting DNAJC27-AS1 can lead to the downregulation of various cellular processes, including cell growth, apoptosis, and angiogenesis.

In addition, its expression is often associated with the negative regulation of cellular processes, such as cell cycle progression and apoptosis. Therefore, targeting DNAJC27-AS1 may be a promising strategy for the development of new anti-cancer drugs.

Potential Biomarkers

DNAJC27-AS1 has also been identified as a potential biomarker for various diseases, including cancer. Its unique expression patterns and strong association with cellular processes make it an attractive target for the development of new diagnostic tools.

In cancer, DNAJC27-AS1 has been shown to be overexpressed in various tissues and clinical settings. For example, it has been shown to be overexpressed in the placenta, which is a potential indicator of poor prognosis in breast cancer. Similarly, it has been shown to be overexpressed in brain, which may contribute to the development of neurodegenerative diseases.

In addition, DNAJC27-AS1 has been shown to be involved in the regulation of cellular processes, including cell apoptosis. Its expression has been associated with the negative regulation of cell apoptosis, which may contribute to the development of neurodegenerative diseases.

Conclusion

In conclusion, DNAJC27-AS1 is a non-protein coding RNA molecule with unique structure and expression patterns. Its potential as a drug target and biomarker make it an attractive target for the development of new therapeutic approaches. Further studies are needed to fully understand its biology and develop new strategies for the development of new drugs.

Protein Name: DNAJC27 Antisense RNA 1

The "DNAJC27-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAJC27-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets